Durect corporation reports third quarter 2024 financial results and provides business update

-     seeking to initiate phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     webcast of earnings call today, november 13 at 4:30 p.m. et cupertino, calif.
DRRX Ratings Summary
DRRX Quant Ranking